Viemed Healthcare Announces Second Published Non-Invasive Ventilation Study
September 16 2021 - 10:43AM
Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD and
TSX: VMD.TO), a home medical equipment supplier and the nation’s
largest independent provider of ventilation that provides
post-acute respiratory care services, announced another published
non-invasive ventilation study led by Dr. William Frazier, Viemed’s
Chief Medical Officer. The study, entitled “Noninvasive Ventilation
at Home Reduces Mortality in COPD With CRF”, was published on
September 15, 2021, in the on-line edition of The American Journal
of Managed Care, a respected, peer reviewed journal.
(https://www.ajmc.com/view/noninvasive-ventilation-at-home-reduces-mortality-in-copd-with-crf)
Patients with chronic respiratory failure
secondary to chronic obstructive pulmonary disease (“COPD-CRF”)
have limited treatment options and poor health outcomes. This study
examined the effect of noninvasive ventilation at home (“NIVH”) on
all-cause mortality, hospitalizations, and emergency department
(“ED”) visits in patients with COPD-CRF. The results demonstrated
that patients with COPD-CRF who received NIVH had statistically
significant and clinically meaningful reductions in
hospitalizations and ED visits compared with patients not treated
with NIVH. Furthermore, the data suggests that earlier NIVH
treatment following CRF diagnosis is associated with a large
reduction in all-cause mortality.
The highlights of the results are as
follows:
- Patients with COPD and CRF who were
prescribed NIVH had statistically significant reductions in risk of
death (38.3%), hospitalizations (21.0%), and ED visits (42.9%)
compared with similar patients not treated with NIVH.
- NIVH is associated with a 1-year
risk difference of 13.0% for mortality, 8.4% for first
hospitalization, and 17.6% for first ED visit, yielding relative
risk reductions of 30.7%, 12.9%, and 20.1%, respectively. The
numbers needed to treat are 7.7 to prevent a death, 12.0 to prevent
a first hospitalization, and 5.7 to prevent a first ED visit.
All data for the study was obtained from the
Medicare Limited Data Set and included patients who were diagnosed
with COPD and CRF between 2012 and 2017.
“We are very pleased to once again see published
evidence that supports the clinical efficacy of NIVH on the highest
risk, chronically ill respiratory patients, and are excited to
continue to share these results with the medical community,” said
Casey Hoyt, Viemed’s CEO. “These results confirm the findings of a
separate study (https://doi.org/10.1016/j.rmed.2020.106291)
published in December 2020 which used different statistical methods
and studied a different patient population than that used in the
current study. While both of these studies used data from the
Medicare Limited Data set, our ongoing sponsored study on outcomes
associated with NIVH use in COPD-CRF includes data from the
complete Medicare data set from 2016 through 2020. We expect to be
sharing the results with physicians, payors, patients, and the rest
of our industry peers in the near future.”
ABOUT VIEMED HEALTHCARE, INC.
Viemed is a provider of in-home medical
equipment and post-acute respiratory healthcare services in the
United States. Viemed’s service offerings are focused on effective
in-home treatment with clinical practitioners providing therapy and
counseling to patients in their homes using cutting edge
technology. Visit our website at www.viemed.com.
For further information, please contact:
Glen AkselrodBristol Capital905-326-1888glen@bristolir.com
Todd ZehnderChief Operating OfficerViemed Healthcare,
Inc.337-504-3802investorinfo@viemed.com
Forward-Looking Statements
Certain statements contained in this press
release may constitute “forward-looking statements” within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995 or “forward-looking information” as such term is defined in
applicable Canadian securities legislation (collectively,
“forward-looking statements”). Often, but not always,
forward-looking statements can be identified by the use of words
such as “plans”, “expects”, “is expected”, “budget”, “potential”,
“scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”,
“believes”, or “projects”, or the negatives thereof or variations
of such words and phrases or statements that certain actions,
events or results “will”, “should”, “may”, “could”, “would”,
“might” or “will be taken”, “occur” or “be achieved” or the
negative of these terms or comparable terminology. All statements
other than statements of historical fact, including those that
express, or involve discussions as to, expectations, beliefs,
plans, objectives, assumptions or future events or performance,
including the Company’s expectations on sharing study results in
the future, are not historical facts and may be forward-looking
statements and may involve estimates, assumptions and uncertainties
that could cause actual results or outcomes to differ materially
from those expressed in the forward-looking statements. Such
statements reflect the Company's current views and intentions with
respect to future events, and current information available to the
Company, and are subject to certain risks, uncertainties and
assumptions. Many factors could cause the actual results,
performance or achievements that may be expressed or implied by
such forward-looking statements to vary from those described herein
should one or more of these risks or uncertainties materialize.
These factors include, without limitation: the general business,
market and economic conditions in the regions in which the Company
operates; the impact of the COVID-19 pandemic and the actions taken
by governmental authorities, individuals and companies in response
to the pandemic on our business, financial condition and results of
operations, including on the Company's patient base, revenues,
employees, and equipment and supplies; significant capital
requirements and operating risks that the Company may be subject
to; the ability of the Company to implement business strategies and
pursue business opportunities; volatility in the market price of
the Company's common shares; the Company’s novel business model;
the risk that the clinical application of treatments that
demonstrate positive results in a study may not be positively
replicated or that such test results may not be predictive of
actual treatment results or may not result in the adoption of such
treatments by providers; the state of the capital markets; the
availability of funds and resources to pursue operations;
reductions in reimbursement rates and audits of reimbursement
claims by various governmental and private payor entities;
dependence on few payors; possible new drug discoveries; dependence
on key suppliers and the recall of certain Royal Philips BiPAP and
CPAP devices and ventilators that we distribute and sell; granting
of permits and licenses in a highly regulated business;
competition; low profit market segments; disruptions in or attacks
(including cyber-attacks) on the Company's information technology,
internet, network access or other voice or data communications
systems or services; the evolution of various types of fraud or
other criminal behavior to which the Company is exposed; the
failure of third parties to comply with their obligations;
difficulty integrating newly acquired businesses; the impact of new
and changes to, or application of, current laws and regulations;
the overall difficult litigation and regulatory environment;
increased competition; changes in foreign currency rates; increased
funding costs and market volatility due to market illiquidity and
competition for funding; critical accounting estimates and changes
to accounting standards, policies, and methods used by the Company;
the Company’s status as an emerging growth company; and the
occurrence of natural and unnatural catastrophic events or health
epidemics or concerns, such as the COVID-19 pandemic, and claims
resulting from such events or concerns; as well as those risk
factors discussed or referred to in the Company’s disclosure
documents filed with the U.S. Securities and Exchange Commission
(the “SEC”) available on the SEC’s website at www.sec.gov,
including the Company’s most recent Annual Report on Form 10-K and
Quarterly Report on Form 10-Q, and with the securities regulatory
authorities in certain provinces of Canada available at
www.sedar.com. Should any factor affect the Company in an
unexpected manner, or should assumptions underlying the
forward-looking statements prove incorrect, the actual results or
events may differ materially from the results or events predicted.
Any such forward-looking statements are expressly qualified in
their entirety by this cautionary statement. Moreover, the Company
does not assume responsibility for the accuracy or completeness of
such forward-looking statements. The forward-looking statements
included in this press release are made as of the date of this
press release and the Company undertakes no obligation to publicly
update or revise any forward-looking statements, other than as
required by applicable law.
VieMed Healthcare (NASDAQ:VMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
VieMed Healthcare (NASDAQ:VMD)
Historical Stock Chart
From Sep 2023 to Sep 2024